Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor
1996

Study of Topotecan's Bioavailability and Pharmacokinetics

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): JHM Schellens, GJ Creemers, JH Beijnen, H Rosing, M de Boer-Dennert, M McDonald, B Davies, J Verweij

Primary Institution: Rotterdam Cancer Institute

Hypothesis

The study aims to explore the bioavailability and pharmacokinetics of oral topotecan in patients with solid tumors.

Conclusion

The bioavailability of topotecan after oral administration is significant, suggesting it may enable chronic oral treatment.

Supporting Evidence

  • The bioavailability of topotecan after oral administration was found to be 30% ± 7.7%.
  • The time to maximum plasma concentration after oral administration was 0.78 hours.
  • Patients tolerated the oral drinking solution well without significant acute side effects.
  • Nine out of twelve patients had documented liver metastases.
  • The study suggests that chronic oral administration of topotecan may be beneficial.

Takeaway

This study looked at how well a cancer drug called topotecan works when taken by mouth, and it found that it can be absorbed well into the body.

Methodology

A two-part crossover study was conducted where 12 patients received both oral and intravenous doses of topotecan.

Limitations

The study had a small sample size and the bioavailability was calculated using AUC(t) instead of AUC extrapolated to infinity.

Participant Demographics

The study included 12 patients (7 males and 5 females) with a mean age of 62 years, primarily with metastatic colon cancer.

Statistical Information

P-Value

0.002

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication